Group 1 - Shouyao Holdings is planning to issue H-shares and list on the Hong Kong Stock Exchange, with discussions ongoing with intermediaries regarding the specifics of the listing [1] - Jiangsu Guoxin's subsidiary, Guoxin Mazhou, has completed the trial operation of a 1000MW coal-fired power unit, which is set to officially commence operations on December 12, 2025 [2] - Yuekang Pharmaceutical's mRNA tumor vaccine has received clinical trial approval from the National Medical Products Administration for treating advanced solid tumors [3] Group 2 - Dongli New Science plans to invest 666 million yuan in the restructuring of SAIC Hongyan, acquiring approximately 14.66% equity post-restructuring [4] - Longsheng Technology is set to invest approximately 350 million yuan in the establishment of an intelligent robot innovation center in Wuxi [5] - Shangwei Co. has received a government subsidy of 2.212 million yuan, which accounts for 13.53% of its audited net profit for 2024 [6] Group 3 - Anglikang has received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for a supplemental application for Sacubitril/Valsartan Sodium Tablets [7] - Guangzhou Development has received acceptance notices for the registration of 8 billion yuan in medium-term notes and 6 billion yuan in short-term financing bonds [8] - Kebo Da plans to increase capital by 21.2 million euros (approximately 174 million yuan) in its wholly-owned subsidiary in Germany [9][10] Group 4 - Changguang Huaxin has received a total of 11.6672 million yuan in government subsidies, including 8.0552 million yuan related to income [11] - Haizheng Pharmaceutical's subsidiary has received a European Pharmacopoeia suitability certificate for its raw material [12] - Qianjin Pharmaceutical's subsidiary has received a drug registration certificate for Lurasidone Hydrochloride Tablets, used for treating schizophrenia [13] Group 5 - Daimai Co. has received a warning letter from the Shanghai Securities Regulatory Bureau due to failure to timely disclose a significant event related to a fire incident [14] - ST Changyao's subsidiary has recently ceased production due to financial difficulties and competitive pressures in the photovoltaic industry [15] - Guodian Power is investing in the construction of a 2×1000MW expansion project at the Ganbi Power Plant, with a total dynamic investment of 7.218 billion yuan [16] Group 6 - Kaichuang International's subsidiary has completed the handover of a tuna purse seine vessel, expected to be operational by 2026 [16] - Tieke Rail plans to sign an energy management agreement for a distributed photovoltaic project, which is expected to save approximately 1.441 million yuan in electricity costs over 25 years [18] - Bailian Co. plans to sign a land compensation agreement with Friendship Logistics, with a total compensation of 103 million yuan [19] Group 7 - Dayu Water-saving's subsidiary has been pre-awarded two high-standard farmland construction projects, with total expected amounts of 137 million yuan and 135 million yuan respectively [20] - Tianma Technology reported a total eel output of approximately 1197.15 tons in November, with sales prices ranging from 53,000 yuan/ton to 89,000 yuan/ton [21] - Guorui Technology's subsidiary has been shortlisted for the GXLF project with a bid of 76 million yuan [22] Group 8 - Qingdao Food's deputy general manager has resigned for personal reasons [23] - Guosheng Zhike plans to use up to 900 million yuan of idle funds for cash management [24] - Guodian Nanrui plans to use up to 23 billion yuan of idle funds for entrusted wealth management [25] Group 9 - Jiahuan Energy plans to merge its wholly-owned subsidiary, Zhejiang Jiahuan Hydrogen Peroxide Co., Ltd., through an overall absorption merger [26] - Ganyue Expressway reported vehicle toll service revenue of 309 million yuan for November [27] - Jinling Hotel's chairman has resigned due to work changes [28] Group 10 - Lisheng Pharmaceutical's subsidiary has received drug registration certificates for Apremilast Tablets [29] - Baotai has received a positive opinion from the European Medicines Agency for Gotenfia® for various inflammatory conditions [30] - ST Zhisheng has been awarded a smart city governance project with a bid amount of 104 million yuan [31] Group 11 - Chenxi Aviation and its related personnel have received administrative regulatory measures from the Shaanxi Securities Regulatory Bureau due to financial reporting issues [32] - Portong Medical has appointed Xia Canglan as the new deputy general manager [33] - Maide Medical plans to repurchase shares with a total amount between 20 million and 40 million yuan [34] Group 12 - Jimin Health plans to establish a joint venture with a total investment of 600 million yuan, focusing on AI and software development [35] - Beilu Pharmaceutical has received a drug registration certificate for Pioglitazone Metformin Tablets [36] - Hainan Mining plans to entrust the overall management of the Shiluo Iron Mine to a construction company for three years, with a total contract amount of approximately 818 million yuan [38] Group 13 - Huiyu Pharmaceutical has received a drug registration certificate for Nicardipine Hydrochloride Injection [39] - Baoland has received a government subsidy of 10 million yuan related to income [40] - Qingdao Port has terminated the acquisition of 100% equity in an oil company and 50% equity in Rizhao Shihua due to regulatory concerns [41]

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in three dosages: 10mg, 20mg, and 30mg, indicating successful approval for market entry [1] Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1] - The registration certificates have the following batch numbers: 2025S03538 for 10mg, 2025S03539 for 20mg, and 2025S03540 for 30mg [1]

| 药品名称 | | 阿普米司特片 | | | | --- | --- | --- | --- | --- | | 剂 | 型 | 片 剂 | | | | 规 | 格 | 10mg | 20mg | 30mg | | 注册分类 | | 化学药品4类 | | | | 药品生产企业 | | 天津市中央药业有限公司 | | | | 原药品批准文号 | | 无 | | | | 申请内容 | | 上市许可申请 | | | | 受理号 | | CYHS2401628 | CYHS2401629 | CYHS2401630 | | 审批结论 | | 通过上市许可申请 | | | 三、该药品的相关信息 阿普米司特片适应症为：本品用于治疗符合接受光疗或系统治疗指征的中度至重度斑块 状银屑病的成人患者。 证券代码：002393 证券简称：力生制药 公告编号：2025-084 天津力生制药股份有限公司 关于子公司中央药业药品阿普米司特片 通过上市许可申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"公司"或"本公司"）的 ...

Core Viewpoint - Company Tianjin Central Pharmaceutical Co., Ltd., a subsidiary of Lisheng Pharmaceutical, has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in 10mg, 20mg, and 30mg specifications, indicating successful approval for market access [1] Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1]

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in 10mg, 20mg, and 30mg specifications, indicating successful approval for market entry [1]. Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1].

Core Viewpoint - The company, Lifesun Pharmaceutical (002393.SZ), announced that its subsidiary, Tianjin Central Pharmaceutical Co., Ltd., has received drug registration certificates from the National Medical Products Administration for Apremilast tablets in three dosages: 10mg, 20mg, and 30mg, indicating successful approval for market entry [1] Group 1 - The drug Apremilast is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy [1] - The registration certificates have the following batch numbers: 2025S03538 for 10mg, 2025S03539 for 20mg, and 2025S03540 for 30mg [1]

Core Viewpoint - The announcement indicates that the subsidiary of the company, Central Pharmaceutical, has received a drug registration certificate from the National Medical Products Administration for Apremilast tablets in 10mg, 20mg, and 30mg specifications, which has passed the marketing authorization application [1] Group 1 - The drug is classified as a Class 4 chemical drug and is intended for the treatment of moderate to severe plaque psoriasis in adult patients [1] - The approval will enrich the company's product line for psoriasis treatment and expand market sales [1] - The future performance impact is expected to be positive, although drug sales may be influenced by market conditions and other factors, leading to uncertainty [1]

Core Viewpoint - The announcement from the Shaanxi Provincial Drug Administration details the results of GMP compliance inspections for three pharmaceutical companies, indicating varying levels of compliance with regulatory standards [2] Group 1: Company Compliance Results - Shaanxi Buchang Pharmaceutical Co., Ltd. was found to be compliant with GMP requirements during inspections conducted from September 16 to September 19, 2025, covering tablet production lines [2] - Xi'an Boai Pharmaceutical Co., Ltd. was found to be non-compliant with GMP requirements during inspections conducted from October 13 to October 17, 2025, focusing on raw material production lines [2] - Shaanxi Fujie Pharmaceutical Co., Ltd. was found to be compliant with GMP requirements during inspections conducted from October 28 to November 1, 2025, covering multiple production lines for raw materials [2]

Market Overview - On December 8, the Tianjin state-owned enterprise reform sector fell by 0.59% compared to the previous trading day, with Haitai Development leading the decline [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Stock Performance - Key stocks in the Tianjin state-owned enterprise reform sector showed mixed performance, with notable movements including: - Taida Co., Ltd. (000652) closed at 4.59, up 1.10% with a trading volume of 373,900 shares and a turnover of 172 million yuan [1] - Haitai Development (600082) closed at 4.29, down 10.06% with a trading volume of 75,200 shares [2] - Other stocks like Jinhai New Energy (600821) and Tianjin Port (600717) also experienced slight declines [1][2] Capital Flow Analysis - The Tianjin state-owned enterprise reform sector saw a net outflow of 49.54 million yuan from institutional investors, while retail investors had a net inflow of 28.05 million yuan [2] - The capital flow for key stocks included: - Taida Co., Ltd. had a net inflow of 22.51 million yuan from institutional investors [3] - Tianjin Port (600717) experienced a net inflow of 5.21 million yuan from institutional investors but a net outflow of 13.35 million yuan from retail investors [3]

证券代码：002393 证券简称：力生制药 公告编号：2025-082 天津力生制药股份有限公司 关于回购注销2022年股权激励计划部分激励对象已获授 但尚未解除限售的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于2025年12月05日召开第八 届董事会第二次会议，审议通过了《关于回购注销2022年股权激励计划部分激励对象已获授 但尚未解除限售的限制性股票的议案》。根据《上市公司股权激励管理办法》（以下简称"《管 理办法》"）以及公司《2022年限制性股票激励计划（草案）》（以下简称"《激励计划》"） 相关规定和2022年第五次临时股东大会授权，由于2022年股权激励计划1名激励对象职务变 动，不再符合激励对象条件，公司拟对该激励对象已获授但尚未解除限售的30,016股限制性 股票进行回购注销。现将有关事项说明如下： 4.2022年11月15日，公司于巨潮资讯网（www.cninfo.com.cn）上披露了《监事会关于 公司2022年限制性股票激励计划授予激励对象名单的公示情况说明及 ...